Skip to main content
. 2022 Jun 6;40(34):3952–3964. doi: 10.1200/JCO.22.01003

FIG 2.

FIG 2.

PFS by investigator in the (A) homologous recombination deficiency population and (B) intent-to-treat population and PFS by BICR for the same populations (C and D, respectively). For BICR analyses, nominal P values, not adjusted for multiplicity, are shown. BICR, blinded independent central review; HR, hazard ratio; NR, not reached; PFS, progression-free survival.